A responder-informed gut microbial consortium enhances anti-PD-1 efficacy in a mouse cancer model

Abstract

Aim: Immune checkpoint inhibitors (ICIs), particularly anti-programmed cell death protein 1 (PD-1) therapy, have improved cancer treatment outcomes, yet durable benefit is achieved in only a subset of patients. Growing evidence implicates the gut microbiome as a modulator of ICI responsiveness, but defined and experimentally validated microbial strategies remain limited. This study aimed to identify responder-associated gut microbes and to evaluate a defined bacterial consortium for enhancing PD-1 blockade efficacy.

Methods: Publicly available shotgun metagenomic datasets from anti-PD-1-treated cancer patients were re-analyzed to compare gut microbiome profiles between responders and non-responders. Bacterial taxa reproducibly enriched in responders were selected based on consistency across analytical criteria and cultivability and assembled into a four-strain consortium (UJ-04). The immune-adjuvant potential of UJ-04, alone or combined with anti-PD-1 therapy, was evaluated in a B16-F10 melanoma mouse model, with tumor growth and immune responses assessed by flow cytometry.

Results: Metagenomic re-analysis identified four commensal bacterial taxa consistently enriched in responder patients, forming the defined UJ-04 consortium. While UJ-04 alone showed minimal antitumor activity, combination treatment with anti-PD-1 significantly enhanced tumor growth inhibition compared with anti-PD-1 monotherapy. This effect was accompanied by increased intratumoral CD8⁺ T cells and natural killer cells, with concordant immune trends in peripheral compartments.

Conclusion: A responder-informed, defined microbial consortium functionally translates clinical microbiome associations into in vivo validation and enhances PD-1 blockade efficacy by modulating host antitumor immunity. These findings support defined bacterial consortia as microbiome-based immunomodulatory adjuncts for immunotherapy.

Keywords

Gut microbiota / cancer immunotherapy / immune checkpoint inhibitors / anti-PD-1 / tumor microenvironment / host-microbiome interactions

References

[1] Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment Int Immunopharmacol 2024 143 113365

[2] Minor DR,Kim KB,Karuturi RKM,Kashani-Sabet M. Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas Front Oncol 2023 13 1241917 PMC10725969

[3] Topalian SL,Hodi FS,Brahmer JR.et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab JAMA Oncol 2019 5 1411 20 PMC6659167

[4] Long GV,Larkin J,Schadendorf D.et al. Pooled long-term outcomes with nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma J Clin Oncol 2025 43 938 48

[5] Iranzo P,Callejo A,Assaf JD.et al. Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer Front Med (Lausanne) 2022 9 875974 PMC9189307

[6] Marei HE,Hasan A,Pozzoli G,Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired Cancer Cell Int 2023 23 64 PMC10088229

[7] Ghosh C,Luong G,Sun Y. A snapshot of the PD-1/PD-L1 pathway J Cancer 2021 12 2735 46 PMC8040720

[8] Parvez A,Choudhary F,Mudgal P.et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment Front Immunol 2023 14 1296341 PMC10722272

[9] Xu S,Shukuya T,Tamura J.et al. Heterogeneous outcomes of immune checkpoint inhibitor rechallenge in patients with NSCLC: a systematic review and meta-analysis JTO Clin Res Rep 2022 3 100309 PMC9011115

[10] Baxter MA,Middleton F,Cagney HP,Petty RD. Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers Br J Cancer 2021 125 1068 79 PMC8505606

[11] Mishima S,Taniguchi H,Akagi K.et al. Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, first edition Int J Clin Oncol 2020 25 217 39 PMC6989445

[12] Valero C,Lee M,Hoen D.et al. Response rates to anti-PD-1 immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase JAMA Oncol 2021 7 739 43 PMC7893543

[13] Reck M,Rodríguez-Abreu D,Robinson AG.et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with pd-l1 tumor proportion score of 50% or greater J Clin Oncol 2019 37 537 46

[14] Carbone DP,Ciuleanu TE,Cobo M.et al. Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA ESMO Open 2025 10 105123 PMC12166824

[15] Barras D,Ghisoni E,Chiffelle J.et al. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8⁺ T-myeloid cell networks in melanoma Sci Immunol 2024 9 eadg7995

[16] Lee JY,Nguyen B,Mukhopadhyay A.et al. Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity Mol Ther Oncolytics 2022 25 174 88 PMC9092072

[17] Dhatchinamoorthy K,Colbert JD,Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation Front Immunol 2021 12 636568 PMC7986854

[18] Wawrzyniak P,Hartman ML. Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors Mol Cancer 2025 24 89 PMC11924818

[19] Nakamura K,Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment Cell Mol Immunol 2020 17 1 12 PMC6952382

[20] Ma Y,Liu Y,Zhi Y.et al. Delivery of CXCL9/10/11 plasmid DNAs promotes the tumor-infiltration of T cells and synergizes with PD1 antibody for treating lung cancer Cancer Nano 2022 13 116

[21] Karin N. CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector T cells, and beyond Front Immunol 2020 11 976 PMC7274023

[22] Kang X,Liu C,Ding Y.et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8⁺ T cells Gut 2023 72 2112 22 PMC10579466

[23] Derosa L,Routy B,Thomas AM.et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer Nat Med 2022 28 315 24 PMC9330544

[24] Tanoue T,Morita S,Plichta DR.et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity Nature 2019 565 600 5

[25] Sivan A,Corrales L,Hubert N.et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy Science 2015 350 1084 9 PMC4873287

[26] McQuade JL,Ologun GO,Arora R,Wargo JA. Gut microbiome modulation via fecal microbiota transplant to augment immunotherapy in patients with melanoma or other cancers Curr Oncol Rep 2020 22 74 PMC7685568

[27] McCulloch JA,Davar D,Rodrigues RR.et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 Nat Med 2022 28 545 56 PMC10246505

[28] Matson V,Fessler J,Bao R.et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients Science 2018 359 104 8 PMC6707353

[29] Routy B,Le Chatelier E,Derosa L.et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors Science 2018 359 91 7

[30] Macandog ADG,Catozzi C,Capone M.et al. Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients Cell Host Microbe 2024 32 2004 2018.e9 PMC11629153

[31] Eisenhauer EA,Therasse P,Bogaerts J.et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 2009 45 228 47

[32] Segata N,Izard J,Waldron L.et al. Metagenomic biomarker discovery and explanation Genome Biol 2011 12 R60 PMC3218848

[33] Hong M,Cho S,Choi KJ,Kim G,Yoon SS. YS Flora®, a comprehensive and multi-purpose collection of human gut microbiome Curr Top Lact Acid Bact Probiotics 2023 9 68 80

[34] Davar D,Dzutsev AK,McCulloch JA.et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients Science 2021 371 595 602 PMC8097968

[35] Gopalakrishnan V,Spencer CN,Nezi L.et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients Science 2018 359 97 103 PMC5827966

[36] Montalban-Arques A,Katkeviciute E,Busenhart P.et al. Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumors Cell Host Microbe 2021 29 1573 1588.e7

[37] Li Y,Elmén L,Segota I.et al. Prebiotic-induced anti-tumor immunity attenuates tumor growth Cell Rep 2020 30 1753 1766.e6 PMC7053418

[38] Lee KA,Thomas AM,Bolte LA.et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma Nat Med 2022 28 535 44 PMC8938272

[39] Lin Y,Xie M,Lau HC.et al. Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response Med 2025 6 100530

[40] Luu M,Riester Z,Baldrich A.et al. Microbial short-chain fatty acids modulate CD8⁺ T cell responses and improve adoptive immunotherapy for cancer Nat Commun 2021 12 4077 PMC8249424

[41] Luu M,Weigand K,Wedi F.et al. Regulation of the effector function of CD8⁺ T cells by gut microbiota-derived metabolite butyrate Sci Rep 2018 8 14430 PMC6158259

[42] Waaler J,Mygland L,Tveita A.et al. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models Commun Biol 2020 3 196 PMC7181813

[43] Turk MJ,Guevara-Patiño JA,Rizzuto GA,Engelhorn ME,Sakaguchi S,Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells J Exp Med 2004 200 771 82 PMC2211964

[44] Tokunaga R,Zhang W,Naseem M.et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy Cancer Treat Rev 2018 63 40 7 PMC5801162

[45] Groom JR,Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions Immunol Cell Biol 2011 89 207 15 PMC3863330

[46] Chow MT,Ozga AJ,Servis RL.et al. Intratumoral activity of the CXCR3 Chemokine system is required for the efficacy of anti-PD-1 therapy Immunity 2019 50 1498 1512.e5 PMC6527362

[47] Grasso CS,Tsoi J,Onyshchenko M.et al. Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma Cancer Cell 2020 38 500 515.e3 PMC7872287

[48] Baruch EN,Youngster I,Ben-Betzalel G.et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients Science 2021 371 602 9

[49] Pi Z,Liu W,Song C.et al. Multi-level insights into the immuno-oncology-microbiome axis: from biotechnology to novel therapies Imeta 2024 3 e240 PMC11487608

[50] Liu W,Pi Z,Mao W. Beyond probiotics: postbiotics sensitize cancer cells to immune checkpoint inhibitors Trends Cancer 2024 10 5 7